A Young Patient with HNF1A-MODY and an Elevated HbA1c

Abstract

Background Maturity-onset diabetes of the young (MODY) is the predominant form of monogenic diabetes, affecting 1 to 5% of diabetes patients. It has autosomal dominant inheritance but occasional de novo mutations. Its clinical features encompass early-onset hyperglycemia, residual pancreatic function, and absence of insulin resistance or beta cell autoimmunity, which are managed primarily with glucose-lowering medications. Increasing awareness of MODY's clinical importance among health care professionals, researchers, and policymakers may enhance screening and diagnostic approaches.

Case Presentation We describe the case of a 16-year-old adolescent boy presenting with polyuria and polydipsia. He had no significant past medical history but a notable family history of diabetes, including prediabetes and type 2 diabetes, across three generations. On evaluation, his vitals were stable. Initial investigations revealed hyperglycemia with a point-of-care glucose of 222 mg/dL, HbA1c of 10.4%, and no ketonuria. C-peptide levels were 0.9 ng/mL, and diabetes autoantibodies were negative. The patient was started on insulin therapy and transitioned to basal-bolus insulin. Genetic testing was performed due to strong familial history and absence of autoantibodies, revealing a heterozygous HNF1A gene mutation consistent with HNF1A-MODY. He was switched to gliclazide 60 mg daily, achieving excellent glycemic control with an HbA1c of 5.3% at 3 months of follow-up. First-degree relatives were referred for MODY genetic testing.

Conclusion In HNF1A–MODY, the glycemic profile typically presents with slight fasting hyperglycemia and notably elevated glucose levels post-glucose intake, accompanied by a gradual decline in insulin secretion and deteriorating glucose regulation, necessitating treatment. It is generally uncommon to have significant hyperglycemia and elevation of HbA1c in MODY patients, as seen in the case discussed. Clinicians need a comprehensive grasp of MODY's epidemiology and pathogenesis to precisely diagnose patients, tailor individualized treatment plans and monitoring, and screen relatives of those affected by diabetes mellitus.

Keywords

maturity-onset diabetes - MODY - monogenic diabetes - HNF1A gene

Patient Consent Statement

Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Authors' Contributions

H.F. contributed to the drafting of the case report. P.A. clinically reviewed and managed the patient and, as the corresponding author, supervised the preparation of the manuscript and coordinated the submission process. All authors reviewed and approved the final version of the case report.

Compliance with Ethical Principles

No prior ethical approval is required for single case reports and small series provided informed consent is obtained from the patients.

Publikationsverlauf

Artikel online veröffentlicht:
17. April 2025

• References

• 1 Broome DT, Pantalone KM, Kashyap SR, Philipson LH. Approach to the patient with MODY-monogenic diabetes. J Clin Endocrinol Metab 2021; 106 (01) 237-250
• 2 Bacon S, Kyithar MP, Rizvi SR. et al. Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort. Diabet Med 2016; 33 (07) 976-984
• 3 Frayling TM, Bulamn MP, Ellard S. et al. Mutations in the hepatocyte nuclear factor-1α gene are a common cause of maturity-onset diabetes of the young in the U.K. Diabetes 1997; 46 (04) 720-725
• 4 Chakera AJ, Steele AM, Gloyn AL. et al. Recognition and management of individuals with hyperglycemia because of a heterozygous glucokinase mutation. Diabetes Care 2015; 38 (07) 1383-1392
• 5 Zhao Q, Ding L, Yang Y. et al. Clinical characteristics of patients with HNF1-alpha MODY: a literature review and retrospective chart review. Front Endocrinol (Lausanne) 2022; 13: 900489
• 6 Katte JC, Dehayem MY, Colclough K, Sobngwi E. Treatment switch from multiple daily insulin injections to sulphonylureas in an African young adult diagnosed with HNF1A MODY: a case report. J Med Case Rep 2024; 18 (01) 506
• 7 Tuomi T, Honkanen EH, Isomaa B, Sarelin L, Groop LC. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3. Diabetes Care 2006; 29 (02) 189-194
• 8 Fajans SS, Bell GI. MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care 2011; 34 (08) 1878-1884
• 9 Steele AM, Shields BM, Shepherd M, Ellard S, Hattersley AT, Pearson ER. Increased all-cause and cardiovascular mortality in monogenic diabetes as a result of mutations in the HNF1A gene. Diabet Med 2010; 27 (02) 157-161
• 10 Lumb AN, Gallen IW. Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1). Diabet Med 2009; 26 (02) 189-190
• 11 Christensen AS, Hædersdal S, Støy J. et al. Efficacy and safety of glimepiride with or without linagliptin treatment in patients with HNF1A diabetes (maturity-onset diabetes of the young type 3): A randomized, double-blinded, placebo-controlled, crossover trial (GLIMLINA). Diabetes Care 2020; 43 (09) 2025-2033